Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
about
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
P2860
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacovigilance during ibrut ...... in routine clinical practice.
@en
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia
@nl
type
label
Pharmacovigilance during ibrut ...... in routine clinical practice.
@en
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia
@nl
prefLabel
Pharmacovigilance during ibrut ...... in routine clinical practice.
@en
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia
@nl
P2093
P2860
P1433
P1476
Pharmacovigilance during ibrut ...... in routine clinical practice.
@en
P2093
Asher Chanan-Khan
Deborah A Bowen
Gabriel T Bartoo
Heidi D Finnes
Julianna A Merten
Kari G Chaffee
Matthew D Smith
Michael Conte
Neil E Kay
P2860
P304
P356
10.1080/10428194.2016.1251592
P577
2016-11-08T00:00:00Z